Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ASPH | Q12797 | 3/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 3/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | TET3 | O43151 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.36 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.36 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.36 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10765922 | 0.81 | KDM4E (0.46) | NAPRTKDM4EASPHKDM8CES2 | |
| SCHEMBL10373429 | 0.81 | KDM4E (0.60) | NAPRTKDM4EASPHKDM8CES2 | |
| SCHEMBL5036110 | 0.81 | NAPRT (0.38) | NAPRTKDM4EASPHKDM8CES2 | |
| SCHEMBL16414338 | 0.81 | NAPRT (0.38) | NAPRTKDM4EASPHKDM8CES2 | |
| SCHEMBL2338841 | 0.81 | NAPRT (0.38) | NAPRTKDM4EASPHKDM8CES2 | |
| SCHEMBL1478308 | 0.79 | SMN1; SMN2 (0.46) | NAPRTKDM4EASPHKDM8CES2 | |
| SCHEMBL17611245 | 0.79 | NAPRT (0.46) | NAPRTKDM4EASPHKDM8KMO | |
| SCHEMBL198077 | 0.79 | NAPRT (0.46) | NAPRTKDM4EASPHKDM8KMO | |
| SCHEMBL21826438 | 0.79 | KDM4E (0.44) | NAPRTKDM4EASPHKDM8CES2 | |
| SCHEMBL31281607 | 0.79 | NAPRT (0.46) | NAPRTKDM4EASPHKDM8KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018112840-A1 | 6, 5-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018112842-A1 | 6,6-FUSED HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018112843-A1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2017107087-A1 | 6, 7-DIHYDRO-5H-PYRROLO [3, 4-B] PYRIDIN-5-ONEALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | disclosed |
| EP-2627637-B1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| EP-2627637-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| WO-2012131037-A1 | RADIOLABELLED FLUMAZENIL DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012131037-A1 | RADIOLABELLED FLUMAZENIL DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-10-04 | — | — | WO | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
| WO-2012049190-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | WO | disclosed |
| EP-1699767-A4 | PROCESS FOR THE PREPARATION OF PYRIDOPYRIMIDONES | SCIOS INC (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7119199-B2 | Process for the preparation of pyridopyrimidones | SCIOS INC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1699767-A2 | PROCESS FOR THE PREPARATION OF PYRIDOPYRIMIDONES | Scios, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20050176957-A1 | Process for the preparation of pyridopyrimidones | SCIOS INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2005065416-A2 | PROCESS FOR THE PREPARATION OF PYRIDOPYRIMIDONES | SCIOS INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176957-A1 | Process for the preparation of pyridopyrimidones | PDXK, PNPO, AGPS | NAPRT 136/4885KDM4E 2063/4885ASPH 1781/4885 |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | APOB, CETP, NPC1L1 | NAPRT 577/4885KDM4E 1664/4885ASPH 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.